Metraipolis › archive › dc_15f49899ebf3

Real-World Safety and Early Effectiveness of First-Line Enfortumab Vedotin Plus Pembrolizumab with Routine Dexamethasone Premedication in Advanced Urothelial… — Europe PMC PMID:41827674

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41827674
DOI
10.3390/cancers18050739
License (as archived)
solo-consultazione
Archived
2026-11-05T08:00:38.389Z
SHA-256 of the archived text
0b1257daab5d0cc7bb18a421f072111718a2e12f6622a4bc6aac527598384285
Stable URL of this page
https://metraipolis.com/documento/dc_15f49899ebf3

How to cite

Real-World Safety and Early Effectiveness of First-Line Enfortumab Vedotin Plus Pembrolizumab with Routine Dexamethasone Premedication in Advanced Urothelial… — Europe PMC PMID:41827674 — Europe PMC (en), https://europepmc.org/article/MED/41827674 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_15f49899ebf3 (Metraipolis archive dc_15f49899ebf3, sha256 0b1257daab5d0cc7bb18a421f072111718a2e12f6622a4bc6aac527598384285)
BibTeX
@misc{dc15f49899ebf3,
  title = {Real-World Safety and Early Effectiveness of First-Line Enfortumab Vedotin Plus Pembrolizumab with Routine Dexamethasone Premedication in Advanced Urothelial… — Europe PMC PMID:41827674},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41827674},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_15f49899ebf3; sha256 0b1257daab5d0cc7bb18a421f072111718a2e12f6622a4bc6aac527598384285},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41827674. Agents can read the archived copy with the MCP tool read_document.